Armata Pharmaceuticals, Inc. (ARMP)
NYSEAMERICAN: ARMP · Real-Time Price · USD
9.47
-1.54 (-13.95%)
At close: Apr 28, 2026, 4:00 PM EDT
9.76
+0.29 (3.12%)
After-hours: Apr 28, 2026, 4:00 PM EDT
Armata Pharmaceuticals Employees
Armata Pharmaceuticals had 60 employees as of December 31, 2024. The number of employees decreased by 6 or -9.09% compared to the previous year.
Employees
60
Change (1Y)
-6
Growth (1Y)
-9.09%
Revenue / Employee
$81,733
Profits / Employee
-$2,896,650
Market Cap
346.73M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Valneva SE | 674 |
| Ginkgo Bioworks Holdings | 485 |
| REGENXBIO | 371 |
| 4D Molecular Therapeutics | 196 |
| Entrada Therapeutics | 152 |
| Aura Biosciences | 113 |
| Prelude Therapeutics | 79 |
| Larimar Therapeutics | 71 |
ARMP News
- 1 day ago - Armata Pharmaceuticals Announces Appointment of Biopharmaceutical Commercial Executive Daniel B. Gilmer, Ph.D. - PRNewsWire
- 4 weeks ago - Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2025 Financial Results - PRNewsWire
- 5 weeks ago - Armata Pharmaceuticals Delays Announcement of Fourth Quarter and Full-Year 2025 Results and Provides Corporate Update - PRNewsWire
- 2 months ago - Armata Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) Designation for AP-SA02 - PRNewsWire
- 3 months ago - Armata Pharmaceuticals Announces End-of-Phase 2 Meeting with FDA and Plans to Advance AP-SA02 to a Phase 3 Superiority Study in Complicated BacteremiaStaphylococcusaureus - PRNewsWire
- 5 months ago - Armata Pharmaceuticals Announces Key Opinion Leader Webinar on S. aureus Bacteremia and AP-SA02 Hosted by Jones Research on November 25th at 10:00am EST - PRNewsWire
- 5 months ago - Armata Pharmaceuticals Announces Third Quarter 2025 Results and Provides Corporate Update - PRNewsWire
- 6 months ago - Armata Pharmaceuticals Announces Formal Commissioning of State-of-the-Art cGMP Phage Manufacturing Facility in Los Angeles, California - PRNewsWire